UB Paderborn / Katalog / Suche / in CDI

HLA-B57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA ® observational database: a cohort study

AIDS research and therapy, 2019-01, Vol.16 (1), p.1-1, Article 1

2019

Link zum Volltext

Verfügbarkeit prüfen

HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects

BMC infectious diseases, 2017-04, Vol.17 (1), p.256-256, Article 256

2017

Link zum Volltext

Verfügbarkeit prüfen

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naive Subjects

The Journal of infectious diseases, 2005-12, Vol.192 (11), p.1921-1930

2005

Link zum Volltext

Verfügbarkeit prüfen

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

PloS one, 2014-05, Vol.9 (5), p.e96187

2014

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing

PloS one, 2014-02, Vol.9 (2), p.e89611-e89611

2014

Link zum Volltext

Verfügbarkeit prüfen

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

AIDS research and human retroviruses, 2018-08, Vol.34 (8), p.672

2018

Link zum Volltext

Verfügbarkeit prüfen

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

AIDS (London), 2009-07, Vol.23 (12), p.1547-1556

2009

Link zum Volltext

Verfügbarkeit prüfen

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment

AIDS (London), 2021-07, Vol.35 (8), p.1201-1208

2021

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

The patient : patient-centered outcomes research, 2021-11, Vol.14 (6), p.849-862

2021

Link zum Volltext

Verfügbarkeit prüfen

Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort

AIDS patient care and STDs, 2021-11, Vol.35 (11), p.419

2021

Link zum Volltext

Verfügbarkeit prüfen

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B5701 Screening as a Risk‐Mitigation Measure

Pharmacotherapy, 2019-01, Vol.39 (1), p.40-54

2019

Link zum Volltext

Verfügbarkeit prüfen

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Journal of neurovirology, 2019-02, Vol.25 (1), p.22-31

2019

Link zum Volltext

Verfügbarkeit prüfen

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

AIDS (London), 2010-08, Vol.24 (13), p.2019-2027

2010

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES

AIDS research and human retroviruses, 2013-02, Vol.29 (2), p.350

2013

Link zum Volltext

Verfügbarkeit prüfen

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

AIDS research and therapy, 2009-04, Vol.6 (1), p.3-3

2009

Link zum Volltext

Verfügbarkeit prüfen

Reply to Carr

The Journal of infectious diseases, 2006-06, Vol.193 (12), p.1742-1743

2006

Link zum Volltext

Verfügbarkeit prüfen

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

Journal of acquired immune deficiency syndromes (1999), 2006-11, Vol.43 (3), p.284

2006

Link zum Volltext

Verfügbarkeit prüfen

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

HIV/AIDS (Auckland), 2017-01, Vol.9, p.51-61

2017

Link zum Volltext

Verfügbarkeit prüfen

Twice-Daily Triple Nucleoside Intensification Treatment with Lamivudine-Zidovudine plus Abacavir Sustains Suppression of Human Immunodeficiency Virus Type 1: Results of the TARGET Study

The Journal of infectious diseases, 2001-02, Vol.183 (4), p.571-578

2001

Link zum Volltext

Verfügbarkeit prüfen

How clean was the KLEAN trial? – Authors' reply

The Lancet (British edition), 2006-11, Vol.368 (9547), p.1571-1571

2006

Link zum Volltext

Verfügbarkeit prüfen

Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen

The Annals of pharmacotherapy, 2004-07, Vol.38 (7-8), p.1314

Shaefer, Mark S

2004

Link zum Volltext

Verfügbarkeit prüfen

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients

Journal of acquired immune deficiency syndromes (1999), 2003-10, Vol.34 (2), p.174

2003

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of tacrolimus in liver transplant patients

Clinical pharmacology and therapeutics, 1995-03, Vol.57 (3), p.281-290

1995

Link zum Volltext

Verfügbarkeit prüfen

Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study

Pharmacotherapy, 2008-03, Vol.28 (3), p.314-322

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

HLA-B57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA ® observational database: a cohort study

HLA-B57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B57:01-negative subjects

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min

Early Virologic Nonresponse to Tenofovir, Abacavir, and Lamivudine in HIV-Infected Antiretroviral-Naive Subjects

Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial

HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencing

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)

Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort

Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B5701 Screening as a Risk‐Mitigation Measure

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study)

Reply to Carr

Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

Twice-Daily Triple Nucleoside Intensification Treatment with Lamivudine-Zidovudine plus Abacavir Sustains Suppression of Human Immunodeficiency Virus Type 1: Results of the TARGET Study

How clean was the KLEAN trial? – Authors' reply

Abacavir/lamivudine/zidovudine continues to be a valid and useful antiretroviral regimen

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients

Pharmacokinetics of tacrolimus in liver transplant patients

Short‐term Safety and Tolerability of a Once‐Daily Fixed‐Dose Abacavir‐Lamivudine Combination versus Twice‐Daily Dosing of Abacavir and Lamivudine as Separate Components: Findings from the ALOHA Study

Suchergebnisse filtern